The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome

作者：Carlioglu Ayse; Kaygusuz Ikbal^*; Karakurt Feridun; Gumus Ilknur Inegol; Uysal Aysel; Kasapoglu Benan; Armutcu Ferah; Uysal Sema; Keskin Esra Aktepe; Koca Cemile

来源：Archives of Gynecology and Obstetrics, 2014, 290(5): 929-935.

DOI：10.1007/s00404-014-3275-8

• Polycystic ovary syndrome
• Platelet activating factor acetyl hydrolyze
• Oxidized LDL
• Paraoxonase1
• Paraoxonase1 phenotypes
• Arylesterase

Purpose To evaluate the platelet activating factor acetyl hydrolyze (PAF-AH), oxidized low-density lipoprotein (ox-LDL), paraoxonase 1 (PON1), arylesterase (ARE) levels and the effects of metformin and Diane-35 (ethinyl oestradiol + cyproterone acetate) therapies on these parameters and to determine the PON1 polymorphisms among PCOS patients. %26lt;br%26gt;Methods Ninety patients with PCOS, age 30, and body mass index-matched healthy controls were included in the study. Patients were divided into three groups: metformin treatment, Diane-35 treatment and no medication groups. The treatment with metformin or Diane-35 was continued for 6 months and all subjects were evaluated with clinical and biochemical parameters 6 months later. One-way Anova test, t test and non-parametric Mann-Whitney U tests were used for statistical analysis. %26lt;br%26gt;Results PAF-AH and ox-LDL levels were statistically significantly higher in untreated PCOS patients than controls, and they were statistically significantly lower in patients treated with metformin or Diane-35 than untreated PCOS patients. In contrast, there were lower PON1 (not statistically significant) and ARE (statistically significant) levels in untreated PCOS patients than the control group and they significantly increased after metformin and Diane-35 treatments. In PCOS patients serum PON1 levels for QQ, QR and RR phenotypes were statistically significantly lower than the control group. %26lt;br%26gt;Conclusion In patients with PCOS, proatherogenic markers increase. The treatment of PCOS with metformin or Diane-35 had positive effects on lipid profile, increased PON1 level, which is a protector from atherosclerosis and decreased the proatherogenic PAF-AH and ox-LDL levels.

• 出版日期2014-11